Abstract: A technique is provided for a graphical user interface on a computer. The technique includes receiving messages individually corresponding to resources being monitored, displaying rows in a table, and generating bar graphs of the messages respectively corresponding to the resources in the rows. Each of the bar graphs displays a color coded scheme to visually distinguish severity of the messages in each of the rows for the resources. The bar graphs display the severity of the messages for one resource per the given row without requiring user intervention to view severities of the messages displayed by the color coded scheme, without requiring user intervention to view a total number of messages for the given row, while maintaining a same row height regardless of the total number of messages for the given row, and without changing a table size including a table height and a table width of the table.

Abstract: A technique is provided for a graphical user interface on a computer. The technique includes receiving messages individually corresponding to resources being monitored, displaying rows in a table, and generating bar graphs of the messages respectively corresponding to the resources in the rows. Each of the bar graphs displays a color coded scheme to visually distinguish severity of the messages in each of the rows for the resources. The bar graphs display the severity of the messages for one resource per the given row without requiring user intervention to view severities of the messages displayed by the color coded scheme, without requiring user intervention to view a total number of messages for the given row, while maintaining a same row height regardless of the total number of messages for the given row, and without changing a table size including a table height and a table width of the table.

Abstract: The present invention is related to the branch of immunology and particularly with the generation of pharmaceutical compositions containing a humanized monoclonal antibody recognizing the leukocyte differentiation antigen CD6. Accordingly with that statement, the purpose of this invention is to provide pharmaceutical compositions which contain a humanized anti-CD6 monoclonal antibody for the diagnosis and treatment of Autoimmune Diseases, particularly the Rheumatoid Arthritis.

Abstract: The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1 (D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types.

Abstract: In one embodiment, a computer-implemented method includes writing, into a tree content column of a tree table, content for a plurality of rows of the tree table. The content spans multiple hierarchical levels, and the content in each of the rows is commonly aligned within the tree content column. A level-indicating icon is associated with each of the hierarchical levels of the tree table. A first level-indicating icon for a first hierarchical level of the tree table is positioned in two or more distinct rows of the tree table having content in the first hierarchical level, and a second level-indicating icon for a second hierarchical level of the tree table is positioned in at least one row of the tree table having content in the second hierarchical level. The tree table is rendered by a computer processor.

Abstract: A technique is provided for a graphical user interface on a computer. The technique includes receiving messages individually corresponding to resources being monitored, displaying rows in a table, and generating bar graphs of the messages respectively corresponding to the resources in the rows. Each of the bar graphs displays a color coded scheme to visually distinguish severity of the messages in each of the rows for the resources. The bar graphs display the severity of the messages for one resource per the given row without requiring user intervention to view severities of the messages displayed by the color coded scheme, without requiring user intervention to view a total number of messages for the given row, while maintaining a same row height regardless of the total number of messages for the given row, and without changing a table size including a table height and a table width of the table.

Abstract: A technique is provided for a graphical user interface on a computer. The technique includes receiving messages individually corresponding to resources being monitored, displaying rows in a table, and generating bar graphs of the messages respectively corresponding to the resources in the rows. Each of the bar graphs displays a color coded scheme to visually distinguish severity of the messages in each of the rows for the resources. The bar graphs display the severity of the messages for one resource per the given row without requiring user intervention to view severities of the messages displayed by the color coded scheme, without requiring user intervention to view a total number of messages for the given row, while maintaining a same row height regardless of the total number of messages for the given row, and without changing a table size including a table height and a table width of the table.

Abstract: A method for displaying a timeline includes receiving, by a processor, a plurality of events and a plurality of time intervals, wherein each of the plurality of events and each of the plurality of time intervals include an associated importance level and determining one or more time periods that correspond to each of the plurality of time intervals. The method also includes displaying the time periods, wherein a color of a background of each time period is based upon the time interval that the time period corresponds to and indicates the associated importance level of the time interval. The method further includes displaying an icon for each of the plurality of events, wherein the icon is indicative of the associated importance level of the event and wherein each icon is disposed in the time period that corresponds to a date of the event.

Abstract: The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1 (D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types.

Abstract: The present invention relates to methods of treatment useful in chronic diseases, by means of the rupture of tolerance to self-antigens and increasing autoimmune response against these antigens. More particularly, the present invention relates to methods useful in the treatment of tumors that are growth dependent on the Epidermal Growth Factor, including non-small cell lung carcinoma. In the present invention a therapeutic combination is revealed that includes the combination of a vaccine against self antigens with a monoclonal antibody against peripheral T cells or a chemotherapeutic drug able to induce a depletion of peripheral T cells.

Abstract: A method for displaying a timeline includes receiving, by a processor, a plurality of events and a plurality of time intervals, wherein each of the plurality of events and each of the plurality of time intervals include an associated importance level and determining one or more time periods that correspond to each of the plurality of time intervals. The method also includes displaying the time periods, wherein a color of a background of each time period is based upon the time interval that the time period corresponds to and indicates the associated importance level of the time interval. The method further includes displaying an icon for each of the plurality of events, wherein the icon is indicative of the associated importance level of the event and wherein each icon is disposed in the time period that corresponds to a date of the event.

Abstract: The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1 (D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types.

Abstract: The present invention is related to the branch of immunology and particularly with the generation of pharmaceutical compositions comprising a humanized monoclonal antibody recognizing the leukocyte differentiation antigen CD6. Accordingly with that statement, the purpose of this invention is to provide pharmaceutical compositions comprising a humanized anti-CD6 monoclonal antibody for the diagnosis and treatment of Lymphoproliferative Syndromes and particularly the B-Cell Chronic Lymphocytic Leukemia. The essence of the invention consist in the application of a humanized Monoclonal Antibody that recognizes the CD6 antigen, the generation of pharmaceutical compositions comprising that antibody being able to induce apoptosis of malignant cells from B-Cell Chronic Lymphocytic Leukemia patients, reaching a clinical and a histological antitumor efficacy. The field of application of the present invention extends to the Oncology.

Abstract: The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1(D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types.

Abstract: This invention discloses means for obtaining immunogenic peptides, polypeptides, proteins, and their corresponding nucleic acid sequences, target cells with vaccine interest, or lysates thereof, without making structural changes in said antigens, through their association with Very Small Size Proteoliposomes. The object of the invention is to provide immunogenic compositions containing peptides, polypeptides, proteins, their corresponding DNA sequences, cells or their lysates and Very Small Size Proteoliposomes (VSSP), which are formed by binding the Outer Membrane Protein Complex (OMPC) of Neisseria meningitidis with gangliosides, by means of hydrophobic links. Additionally, it is stated that these compositions can be formulated alone or in the form of emulsions with the Incomplete Freund's Adjuvant (IFA), and may also be lyophilized.

Abstract: A method of recovering mammalian cell clones adapted to serum and protein-free media is disclosed. The procedure includes a two-stage adaptation process to grow in that condition. A critical protein concentration interval is disclosed in which cells must grow in order to gain the capacity to survive in serum and protein-free condition, once the cells have grown at the critical interval concentrations, subsequent decreases of the concentration will affect neither viability nor cellular doubling time. The critical protein concentration interval is cell line specific. Furthermore, mammalian cells clones are disclosed, which are stable in serum- and protein-free media for at least 40 generations; additionally, clones disclosed express a recombinant product. The cell clones disclosed produce the humanized anti-EGF-R antibody hR3, the humanized anti-CD6 antibody T1hT, the chimeric anti CD3 antibody T3Q, or fragments thereof.

Abstract: The present invention is related to the branch of immunology and particularly with the generation of pharmaceutical compositions containing a humanized monoclonal antibody recognizing the leukocyte differentiation antigen CD6. Accordingly with that statement, the purpose of this invention is to provide pharmaceutical compositions which contain a humanized anti-CD6 monoclonal antibody for the diagnosis and treatment of Autoimmune Diseases, particularly the Rheumatoid Arthritis.

Abstract: The present invention is related to the branch of immunology and particularly with the generation of pharmaceutical compositions comprising a humanized monoclonal antibody recognizing the leukocyte differentiation antigen CD6. Accordingly with that statement, the purpose of this invention is to provide pharmaceutical compositions comprising a humanized anti-CD6 monoclonal antibody for the diagnosis and treatment of Lymphoproliferative Syndromes and particularly the B-Cell Chronic Lymphocytic Leukemia. The essence of the invention consist in the application of a humanized Monoclonal Antibody that recognizes the CD6 antigen, the generation of pharmaceutical compositions comprising that antibody being able to induce apoptosis of malignant cells from B-Cell Chronic Lymphocytic Leukemia patients, reaching a clinical and a histological antitumor efficacy. The field of application of the present invention extends to the Oncology.

Abstract: The present invention describes specific therapeutic compositions, which increase the efficacy of the therapeutic treatment using monoclonal antibodies against the Epidermal Growth Factor Receptor (EGFR) in a combination with type I IFNs.

Abstract: The present invention is related to pharmaceutical compositions based on vaccines and monoclonal antibodies that neutralize the Interleukin-2, which are useful in the treatment of tumors. Particularly the present invention is related to therapeutic formulations able to increase the immunogenicity of the IL-2 conjugated to the carrier protein P64k from the neisseria meningitidis in montanide ISA 51 adjuvant for the induction of IL-2 neutralizing autoantibodies and the effective methods for the treatment of tumors, including breast cancer and melanoma. Furthermore, the present invention is related to therapeutic combination of the IL-2 based vaccine with other cancer vaccines based on specific tumor antigens or tumor growth factors, as well as chemotherapeutics agents or radiotherapy of standard use for cancer treatment.